England's National Institute for Health and Clinical Excellence has removed a ban on two drugs that may help patients with rare life-threatening brain cancer.
Temodal and Gliadel may now be obtained through the National Health Service. The 2005 ban was based on cost-effectiveness.
The Times of London says the ban caused anger because Temodal was actually invented by British scientists with funding from Cancer Research UK.
Gliadel is a wafer that, when placed at the site where a brain tumor was removed, clears remaining cancer cells and keeps the tumor from recurring, the newspaper said.
Both drugs have been available in the United States and Canada.
Ella Pybus, spokeswoman for a consortium of cancer charities, said, "Everyone is relieved."
She said there is "solid evidence" the drugs help patients.
Copyright 2007 by United Press International
Related stories:
Atomic structure of the mammalian 'fatty acid factory' determined
Mammalian fatty acid synthase is one of the most complex molecular synthetic machines in human cells. It is also a promising target for the development of anti-cancer and anti-obesity drugs and the treatment of metabolic disorders. Now researchers at ETH Zurich have determined the atomic structure of a mammalian fatty acid synthase. Their results have just been published in
Science magazine.
Parsing the genome of a deadly brain tumor
The most comprehensive to-date genomic analysis of a cancer – the deadly brain tumor glioblastoma multiforme – shows previously unrecognized changes in genes and provides an overall view of the missteps in the pathways that govern the growth and behavior of cells, said members of The Cancer Genome Atlas Research Network in a report that appears online today in the journal
Nature.
FDA posts list of potential problem drugs
(AP) -- The government on Friday began posting a list of prescription drugs under investigation for potential safety problems, in an effort to better inform doctors and patients.
1 step back ... 2 steps forward
Women with hormone-receptor positive, metastatic breast cancer may take medications for years to help keep their cancer at bay, but when the tumor becomes resistant to anti-hormonal drugs, treatment with chemotherapy becomes the only option. But a study presented today at the 2008 ASCO Breast Cancer Symposium may change this approach. Early data suggests a new treatment approach can "re-sensitize" the tumor, allowing anti-hormonal drugs to do their job once again.
Studies spot numerous undiscovered gene alterations in pancreatic and brain cancers
HHMI investigators have detected a multitude of broken, missing, and overactive genes in pancreatic and brain tumors, in the most detailed genetic survey yet of any human tumor. Some of these genetic changes were previously unknown and could provide new leads for improved diagnosis and therapy for these devastating cancers.
Potential remedy for the 'mental fog' in cancer patients
Cancer patients have complained for years about the mental fog known as chemobrain. Now in animal studies at West Virginia University (WVU), researchers have discovered that injections of N-acetyl cysteine (NAC), an antioxidant, can prevent the memory loss that breast cancer chemotherapy drugs sometimes induce. The WVU researchers' study has just been published in the September issue of the Springer journal
Metabolic Brain Disease.
Unsuccessful drug against anxiety opens a novel gateway for the treatment of cancer
Unsatisfying drug for anxiety reveals scientists a promising novel anti-cancer drug target. Cancer cells have multiple ways to avoid apoptosis, programmed cell death the means by which organisms deal with defective cells. One defense is to produce quantities of phosphatic acid, a phospholipid constituent of cellular membranes.
Scientists produce nanoscale droplets with cancer-fighting implications
(PhysOrg.com) -- UCLA scientists have succeeded in making unique nanoscale droplets that are much smaller than a human cell and can potentially be used to deliver pharmaceuticals.